WBP1 and colorectal carcinoma: To test this hypothesis, we conducted a comprehensive investigation using both genetic and pharmacological approaches, focusing on three key aspects: (1) the relationship between WBP1 expression and clinical outcomes in CRC patients; (2) the impact of WBP1 on mitochondrial function and cell proliferation; and (3) the potential of targeting WBP1 to overcome chemoresistance through ferroptosis induction.